Design Therapeutics stockholders elect directors and ratify auditor at 2025 annual meeting

Design Therapeutics, Inc.

Heather Berger, Ph.D., Rodney Lappe, Ph.D., and John Schmid elected as Class I directors to serve until 2028 annual meeting.
Rodney Lappe received 32,799,677 votes for, 9,948,461 withheld, indicating notable opposition.
Ernst & Young LLP ratified as independent auditor for FY2025 with 53,577,053 votes for, 2,731 against, 1,795 abstentions.
A total of 56,768,678 shares were outstanding and entitled to vote as of the April 15, 2025 record date.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.